Nasdaq Cbay News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nasdaq cbay. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nasdaq Cbay Today - Breaking & Trending Today
StockNews.com initiated coverage on shares of CymaBay Therapeutics (NASDAQ:CBAY – Free Report) in a research report sent to investors on Saturday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. A number of other research firms have also weighed in on CBAY. HC Wainwright reaffirmed a neutral rating and issued a $32.50 […] ....
StockNews.com initiated coverage on shares of CymaBay Therapeutics (NASDAQ:CBAY – Free Report) in a report published on Saturday. The firm issued a sell rating on the biopharmaceutical company’s stock. Other equities research analysts have also recently issued research reports about the company. William Blair cut CymaBay Therapeutics from an outperform rating to a market perform […] ....
Jennison Associates LLC lifted its holdings in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) by 12.3% during the 4th quarter, Holdings Channel.com reports. The firm owned 3,992,711 shares of the biopharmaceutical company’s stock after buying an additional 437,437 shares during the quarter. Jennison Associates LLC’s holdings in CymaBay Therapeutics were worth $94,308,000 at […] ....
Assenagon Asset Management S.A. purchased a new position in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 746,353 shares of the biopharmaceutical company’s stock, valued at approximately $17,629,000. Assenagon Asset Management […] ....
Monashee Investment Management LLC acquired a new stake in CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 75,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,118,000. Several other hedge funds and other […] ....